目的 系統(tǒng)評價抗感顆粒聯(lián)合奧司他韋治療兒童流行性感冒的有效性與安全性。方法 檢索中國學術期刊全文數(shù)據(jù)庫（CNKI）、中國生物醫(yī)學文獻服務系統(tǒng)（SinoMed）、維普中文科技期刊數(shù)據(jù)庫（VIP）、萬方數(shù)據(jù)庫（Wanfang Data）、PubMed、Cochrane Library、Springer Link、Embase數(shù)據(jù)庫中關于抗感顆粒聯(lián)合奧司他韋治療兒童流行性感冒的臨床隨機對照試驗（RCT），檢索時間為建庫至2023年3月。采用Cochrane Handbook中的偏倚風險評估工具和RevMan 5.3軟件進行文獻質量評價與Meta分析。結果 共納入12項RCTs，共計1 201例患者，其中試驗組601例、對照組600例。Meta分析結果顯示，相較于對照組，抗感顆粒聯(lián)合奧司他韋顆粒治療的總有效率更高[RR=1.23，95% CI（1.18，1.29）]，發(fā)熱[MD=-0.42，95% CI（-0.69，-0.15）]、咽痛[MD=-0.31，95% CI（-0.41，-0.21）]積分更低，退熱時間更短[MD=-1.38，95% CI（-1.67，-1.10）]，且兩組比較差異均有統(tǒng)計學意義（P＜0.000 01）；試驗組與對照組的臨床癥狀咳嗽積分[MD=0.19，95% CI（-0.21，0.59），P=0.35]、不良反應發(fā)生率[RR=2.36，95% CI（0.50，11.20），P=0.28]比較，無統(tǒng)計學差異。結論 抗感顆粒聯(lián)合奧司他韋治療兒童流行性感冒療效確切、安全性較好；但本研究尚有一定局限性，上述結論需更高質量的隨機對照研究給予進一步驗證。

Objective To evaluate the efficacy and safety of Kanggan Granule combined with oseltamivir in the treatment of influenza. Methods CNKI, SinoMed, WanFang, VIP, PubMed, Cochrane Library, Springer Link, and Embase were searched by computer to collect the randomized controlled trial(RCT) of Kanggan Granule combined with oseltamivir in the treatment of influenza. The search aimed to identify clinical randomized controlled trials (RCTs) on the combined use of Kanggan granules and oseltamivir for treating influenza in children, the search deadline is from database establishment to March 2023. Meta-analysis performed by RevMan 5.4 software which is provided by Cochrane collaboration network. Result A total of 12 RCTs with 1 201 patients were included, 601 patients in trial group, and 600 patients in control group. The results of Meta-analysis showed that total effective rate of Kanggan Granule combined with oseltamivir in the treatment of influenza was significantly higher than that of oseltamivir alone [RR=1.23, 95%CI(1.18, 1.29), P＜0.000 01]. The fever score [MD=-0.42, 95%CI (-0.69, -0.15), P=0.003], the sore throat score [MD=-0.31, 95%CI (-0.41, -0.21), P＜0.000 01] were significantly lower than that of oseltamivir alone. The duration of fever were significantly shorter than that of oseltamivir alone [MD=-1.38, 95%CI (-1.67, -1.10), P＜0.000 01]. There was no significant difference in the cough score [MD=0.19, 95%CI (-0.21, 0.59), P=0.35] and the incidence of adverse reactions [RR=2.36, 95%CI (0.50, 11.20), P=0.28] between the two groups compared with the use of oseltamivir alone. Conclusion Kanggan Granule can effectively treat children with influenza, and will not increase the incidence of adverse events. However, there are few literatures, which needs further validation by a higher quality randomized controlled study.

R965.3；R969.4

中央高?；究蒲袠I(yè)務專項資助項目（2020-JYB-ZDGG-072）